Eltrombopag ITP denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for eltrombopag itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issues a Duplicate-Therapy Denial for Eltrombopag in ITP

A duplicate-therapy denial means UHC's claims system flagged that another thrombopoietin receptor agonist (TPO-RA) — most commonly romiplostim — is already active on your pharmacy or medical benefit. The insurer's clinical policy generally limits concurrent use of two agents in the same mechanistic class for the same indication. However, there are legitimate clinical reasons a prescriber may transition a patient from one TPO-RA to another, including inadequate platelet response, tolerability problems, or a change in the route of administration that better fits the patient's life. Those reasons must be explicitly documented before the claim can be approved.

## Why This Denial Is Appealable

A duplicate-therapy determination is a coverage decision, not a clinical judgment — it is made algorithmically by comparing drug classes, not by reviewing your individual chart. Federal law gives you the right to have a qualified clinician review the actual medical record. Under ACA §2719 and its implementing regulations, non-grandfathered individual and group plans must provide internal appeal and, if that fails, independent external review. ERISA §503 requires a full-and-fair review for employer-sponsored plans. You generally have approximately 180 days from the denial notice to file an internal appeal, and an external review request typically must follow within 4 months of a final internal denial. An expedited review (decision within 72 hours) is available when your health is at urgent risk.

## Concrete Appeal Steps

1. Request the denial explanation in writing — the Explanation of Benefits (EOB) or denial letter must cite the specific policy provision used. 2. Identify the policy — ask UHC for the exact clinical coverage policy number and version governing TPO-RAs in ITP. Read every criterion. 3. File the internal appeal — submit within the deadline stated on the denial letter. 4. Request external review if the internal appeal is upheld — contact your state insurance commissioner or the federal external-review process depending on your plan type.

## Documentation to Gather

• Diagnosis confirmation: pathology or hematology records establishing chronic ITP with platelet counts over time.
• Prior TPO-RA history: start date, dose-escalation record, peak platelet response, reason for discontinuation or transition (inadequate response, adverse effect, convenience).
• Current medication list: a pharmacy printout showing the prior agent is stopped or being tapered, eliminating the true duplication.
• Prescriber medical-necessity letter: the treating hematologist should explain why eltrombopag specifically is medically necessary for this patient at this time, and why it is not duplicative of any concurrent therapy.

## Criteria-Mapping Structure

Copy each requirement listed in UHC's published TPO-RA coverage policy, then answer each point with a specific chart fact:

| Policy Requirement | Supporting Chart Evidence | |---|---| | Diagnosis of ITP confirmed | [Date of diagnosis + documentation source] | | Prior agent discontinued or not concurrently active | [Last dispense date of prior agent or tapering plan] | | Clinical rationale for agent switch | [Prescriber letter citing specific reason] |

Consult the FDA-approved prescribing information for eltrombopag and UHC's current clinical coverage policy for TPO-RAs for the exact eligibility criteria and thresholds your documentation must satisfy.